Literature DB >> 32896404

Nonsteroidal anti-inflammatory drugs affect the mammary epithelial barrier during inflammation.

G F Sintes1, R M Bruckmaier1, O Wellnitz2.   

Abstract

During inflammation of the mammary gland, the blood-milk barrier, which is predominantly composed of mammary epithelial cells, loses its integrity and gradients between blood and milk cannot be maintained. Nonsteroidal anti-inflammatory drugs (NSAID) are commonly used systemically in combination with local administration of antimicrobials in mastitis treatments of dairy cows to improve the well-being of the cow during the disease. However, the knowledge about their effects on the blood-milk barrier is low. This study aimed to investigate effects of different NSAID, with different selectivity of cyclooxygenase-inhibition, on the transepithelial electrical resistance (TEER) and capacitance, cell viability, and expression of tumor necrosis factor α of bovine mammary epithelial barriers in vitro. Primary mammary epithelial cells of 3 different cows were challenged with lipopolysaccharide (LPS) from Escherichia coli with or without addition of ketoprofen (1.25 mg/mL or 4 mM), flunixin meglumine (1.0 mg/mL or 4 mM), meloxicam (0.25 mg/mL, 0.75 mg/mL, or 4 mM), diclofenac (0.75 mg/mL or 4 mM) or celecoxib (0.05 mg/mL) for 6 h. Concentrations were adapted to comparable relations of the recommended dosage for systemic application. Additionally, a similar molar concentration of all NSAID was used. Lipopolysaccharide with or without NSAID induced a decrease in TEER within 5 h, which returned to control level within 14 h. Viability of cells challenged with LPS only was not affected. However, the cell viability was decreased with increasing concentrations of NSAID and this effect was amplified with simultaneous LPS challenge. Ketoprofen at both dosages, flunixin meglumine at 1.0 mg/mL, and meloxicam at 0.75 mg/mL accelerated the recovery of TEER in comparison to LPS only (return to control level within 9 h). The comparison of NSAID effects at the same molecular quantity of 4 mM showed different effect on the barrier in which ketoprofen accelerated the recovery after LPS-induced barrier opening, whereas meloxicam and diclofenac slowed down the recovery (return to control level after 24 h). In conclusion, NSAID do not prevent the mammary epithelial barrier opening by LPS; however, ketoprofen, flunixin meglumine, and meloxicam obviously support the re-establishment of the barrier integrity. Used in mastitis therapy at an optimized dosage the tested NSAID would likely support the recovery of milk composition. However, an overdose of NSAID would likely cause tissue irritation and in turn, a delayed recovery of the barrier permeability.
Copyright © 2020 American Dairy Science Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  blood–milk barrier; mastitis; nonsteroidal anti-inflammatory drugs

Mesh:

Substances:

Year:  2020        PMID: 32896404     DOI: 10.3168/jds.2020-18818

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  4 in total

1.  The Anti-Inflammation and Anti-Nociception Effect of Ketoprofen in Rats Could Be Strengthened Through Co-Delivery of a H2S Donor, S-Propargyl-Cysteine.

Authors:  Yue Yu; Qinyan Yang; Zhou Wang; Qian Ding; Meng Li; Yudong Fang; Qida He; Yi Zhun Zhu
Journal:  J Inflamm Res       Date:  2021-11-09

Review 2.  Escherichia coli Mastitis in Dairy Cattle: Etiology, Diagnosis, and Treatment Challenges.

Authors:  Débora Brito Goulart; Melha Mellata
Journal:  Front Microbiol       Date:  2022-07-07       Impact factor: 6.064

3.  Anandamide Alters Barrier Integrity of Bovine Vascular Endothelial Cells during Endotoxin Challenge.

Authors:  Carsten C F Walker; Lorraine M Sordillo; G Andres Contreras
Journal:  Antioxidants (Basel)       Date:  2022-07-27

4.  Flunixin Meglumine Reduces Milk Isoprostane Concentrations in Holstein Dairy Cattle Suffering from Acute Coliform Mastitis.

Authors:  Carsten C F Walker; Jill L Brester; Lorraine M Sordillo
Journal:  Antioxidants (Basel)       Date:  2021-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.